Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance
Tα1 improves clinical outcomes in HBV-ACLF by rebalancing the immune response-mitigating excessive inflammation and preventing immune paralysis by modulating T-cell differentiation and cytokine production, thereby breaking the cycle of hyperinflammation and immunosuppression that characterizes ACLF progression.
Authors
- Zi-Ying Lei
- Zhaoxia Hu (ORCID: https://orcid.org/0000-0002-9486-4461)
- Junfeng Chen (ORCID: https://orcid.org/0000-0002-0779-4435)
- Shi-Bo Meng
- BL Lin
- Yuanqiang Zhu (ORCID: https://orcid.org/0009-0000-3395-0115)
- Huijuan Cao (ORCID: https://orcid.org/0000-0001-6533-3488)
- Zhi-hui Li
- Jing Zhang
- Jia-lei Wang
- Li-li Wu
Institutions
- Sun Yat-sen University (CN)
- Ministry of Education (BN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1080/08923973.2026.2641686
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 0.00